[Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)].
Nilotinib (Tasigna) is a second-generation BCR-ABL kinase inhibitor, recently introduced and used for the treatment of chronic or accelerated phase CML patients, intolerant or resistant to imatinib. This treatment represents and important step forward for the disease control of such patients but can lead to side effects, sometimes serious, which can limit its optimal use. We propose here some guidelines that might be of help in daily practice, in order to manage properly these side effects.
Centre régional de lutte contre cancer, Institut Bergonié, 229, cours de l'Argonne, 33076 Bordeaux, France.
G
G
Etienne
B
B
Milpied
D
D
Réa
F
F
Rigal-Huguet
M
M
Tulliez
F-E
FE
Nicolini
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D003875:Drug Eruptions / Q000517:prevention & control; D004347:Drug Interactions; D019008:Drug Resistance, Neoplasm; D004921:Erythropoietin / Q000627:therapeutic use; D005298:Fertility / Q000187:drug effects; D018565:Food-Drug Interactions; D005602:France; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006331:Heart Diseases / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008659:Metabolic Diseases / Q000139:chemically induced / Q000517:prevention & control; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; C498826:nilotinib